Literature DB >> 10087953

Embryonal rhabdomyosarcoma with only numerical chromosome changes. Case report and review of the literature.

P Polito1, P Dal Cin, R Sciot, P Brock, P Van Eyken, H Van den Berghe.   

Abstract

An embryonal rhabdomyosarcoma, presenting as a retroperitoneal mass in a 15-year-old girl, is reported. The histological and immunohistochemical picture was typical, except for the presence of focal chondroid differentiation. Interestingly, expression of the "muscle markers" desmin and alpha-sarcomeric actin was present in the latter areas. Cytogenetic analysis showed a hyperdiploid karyotype without structural chromosome changes. The pertinent literature on the subject is reviewed. Hyperdiploidy of the clonal type seems to occur frequently, but no characteristic karyotype is so far emerging.

Entities:  

Mesh:

Year:  1999        PMID: 10087953     DOI: 10.1016/s0165-4608(98)00168-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma.

Authors:  Romaric Croes; Maria Debiec-Rychter; Kristof Cokelaere; Rita De Vos; Anne Hagemeijer; Raf Sciot
Journal:  Virchows Arch       Date:  2004-11-17       Impact factor: 4.064

2.  Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.

Authors:  Janos Sumegi; Renae Streblow; Robert W Frayer; Paola Dal Cin; Andrew Rosenberg; Aurelia Meloni-Ehrig; Julia A Bridge
Journal:  Genes Chromosomes Cancer       Date:  2010-03       Impact factor: 5.006

3.  Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.

Authors:  Kenichi Kohashi; Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Tomonari Takahira; Yukiko Takahashi; Tatsuro Tajiri; Tomoaki Taguchi; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.